Sarepta Therapeutics (SRPT)
$124.95
2.98 (2.44%)
SRPT Stock Quote Delayed 15 Minutes
Previous Close
$124.95
Market Cap
8.19B
PE Ratio
-42.50
EPS
-2.94
Volume (Avg. Vol.)
1.24M
Day's Range
123.12 - 126.19
52-Week Range
95.21 - 165.87
Dividend & Yield
N/A (N/A)
SRPT Stock Predictions, Articles, and Sarepta Therapeutics News
Nasdaq Today: Apple Loses Ive and the Nasdaq’s Q3 Outlook
The second quarter is the books, at least as far as the stock market is concerned. Here's a look at the Nasdaq today.
5 Top Stock Trades for Monday: STZ, C, UBER
STZ beat on earnings, and the Fed approved higher dividends and buybacks for the bank stocks. Here are the top stock trades heading into next week.
7 Stocks to Buy for Over 20% Upside Potential
If you’re looking for a quick portfolio boost, look no further. Here are 7 stocks to buy with tons of upside according to top analysts.
Why Sarepta Therapeutics (SRPT) Stock Is Sinking Today
Sarepta Therapeutics (SRPT) stock is sinking after the company's late Tuesday announcement that it was offering a $350 million stock ofering.
Why NOW Is the Time to Buy Gene Therapy Stocks
Over the long term, gene therapy stocks will head higher and the last few weeks' of headlines show investors why.
Why Sarepta Therapeutics Stock Is Starting to Shine Again
SRPT stock rebounded nicely from its sub-$100 low last month. More upside is possible as the Sarepta ramps up an important study.
Time to Take Some Profits in Sarepta Therapeutics Stock
Sarepta used the lobbying of patient families to win approval of a drug that may not work against Duchenne muscular dystrophy. It may be time to take profits in SRPT stock..
7 Strong Buy Stocks Analysts Are Upgrading Now, Including Facebook, Inc.
Here we dig down into seven intriguing stock rating upgrades from the Street. Why now? Why are analysts turning bullish on these stocks? All seven of these stocks share a 'Strong Buy' analyst consensus rating from the Street. The result: you can be confident that these stocks are the crème de la crème.
Why Sarepta Therapeutics Inc Stock is Sliding Today
Sarepta Therapeutics (SRPT) stock was hit hard on Friday after reports claim one of its studies was put on hold due to an adverse event.
Sarepta Therapeutics Inc (SRPT) Soars on Q2 Revenue, Forecast
Sarepta Therapeutics (SRPT) stock was flying high on Thursday following the release of its earnings report for the second quarter of 2017.
Sarepta Therapeutics Inc (SRPT) Stock Heads Higher on Analyst Upgrade
Sarepta Therapeutics Inc (SRPT) stock was up on Thursday following an upgrade and price target increase from Leerink Swann.
Buy the SPDR S&P Biotech (ETF) (XBI) TODAY – Here’s Why
Biotech stocks and the SPDR S&P Biotech ETF (XBI) just shook off a major bugaboo in Hillary Clinton. The XBI ETF will soar as a result.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
C
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!
